medigraphic.com
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2021, Number 1

Next >>

Alerg Asma Inmunol Pediatr 2021; 30 (1)

Advances in intralymphatic immunotherapy, aspirin-exacerbated respiratory disease and prevention of allergic disease

Huerta HRE

Language: Spanish
References: 4
Page: 3-4
PDF size: 130.24 Kb.





REFERENCES

  1. Tuttle KL, Schneider TR, Henrickson SE, Morris D, Abonia JP, Spergel JM et al. Aspirin-exacerbated respiratory disease: not always "adult- onset". J Allergy Clin Immunol Pract. 2016; 4 (4): 756-758.

  2. Spoor J, Farajifard H, Rezaei. Congenital neutropenia and primary immunodeficiency diseases. Crit Rev Oncol Hematol. 2019; 133: 149-162.

  3. Testa D, Di Bari M, Nunziata M, De Cristofaro F, Massaro G, Marcuccio G, Motta G. Allergic rhinitis and asthma assessment of risk factors in pediatric patients: A systematic review. Int J Pediatr Otorhinolaryngol. 2020; 129: 109759.

  4. Weinfeld D, Westin U, Hellkvist L, Mellqvist UH, Jacobsson I, Lars?Olaf Cardell LO. A preseason booster prolongs the increase of allergen specific IgG4 levels, after basic allergen intralymphatic immunotherapy, against grass pollen seasonal allergy. Allergy Asthma Clin Immunol. 2020; 16: 31. Available in: https://doi.org/10.1186/s13223-020-00427-z.




2020     |     www.medigraphic.com